Philip Adamson, MD, PhD, serves as Chief Medical Officer at CVRx, Inc., a medical device company pioneering innovative therapies for hypertension and heart failure. A board-certified cardiologist with over 25 years of experience, Dr. Adamson earned his medical degree from the University of Oklahoma and completed his residency and fellowship in cardiology at the University of California, San Diego. His early career focused on advanced heart failure management, where he developed expertise in neuromodulation and device-based therapies, publishing extensively in leading journals such as the New England Journal of Medicine and Circulation. Prior to joining CVRx in 2022, Dr. Adamson held pivotal leadership roles, including Chief Medical Officer for Abbott's Heart Failure division, where he oversaw global clinical development and regulatory strategies for groundbreaking devices like the CardioMEMS HF System. At Corvia Medical and St. Jude Medical, he spearheaded clinical trials that advanced interatrial shunt therapies and cardiac resynchronization, contributing to FDA approvals and landmark studies demonstrating improved patient outcomes. His achievements include over 200 peer-reviewed publications, patents in cardiovascular neuromodulation, and leadership positions in organizations like the Heart Failure Society of America. At CVRx, Dr. Adamson drives the medical strategy for the Barostim Neo System, the first FDA-approved baroreflex activation therapy for heart failure patients with reduced ejection fraction. Under his guidance, the company has expanded clinical evidence through pivotal trials like BeAT-HF and ongoing studies targeting hypertension, positioning CVRx as a leader in addressing unmet needs in cardiovascular care. His vision integrates cutting-edge science with practical clinical application to transform patient lives.